New Pharmaceutical Targets to Counteract Chronic Inflammation
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: closed (20 April 2024) | Viewed by 2075
Special Issue Editors
Interests: organic synthesis; biomimetic agents; uPA-uPAR system; chronic inflammation; retinal diseases
Interests: bioinorganic chemistry; artificial metalloenzymes; bioactive peptides; angiogenesis; chronic inflammation; uPA-uPAR system
Interests: biomimetic agents; artificial metalloenzymes; organic synthesis; drug discovery; angiogenesis; chronic inflammation
Special Issues, Collections and Topics in MDPI journals
2. Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy
Interests: chronic kidney disease (CKD); chronic inflammation; glomerulonephritis; kidney transplantation; acute kidney disease (AKI)
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Inflammation is a protective response of organisms to harmful stimuli including pathogens, damaged cells, and toxic compounds. While finely regulated in a healthy organism, uncontrolled inflammation may become chronic, contributing to the onset of a large number of pathological conditions, spanning from cancer to autoimmune disorders, from diabetes-related complications to infections, from kidney to ocular diseases, and to a variety of age-related degenerative conditions. For many of these pathologies, therapeutic intervention is frequently absent or inadequate. Over the last years, molecular understanding of the mechanisms and signalling pathways leading to chronic inflammation has enabled the identification of new, general and effective pharmaceutic targets (proteolytic enzymes, Toll-like receptors, inflammatory factors, growth factors, and inflammatory metabolites) to be exploited for innovative treatments of inflammatory diseases.
The goal of this Special Issue is to highlight and collate scientific publications and reviews on interesting pharmaceutical studies (regarding the identification of new pharmaceutical targets, innovative pharmaceutic treatments and formulations, and insights into the mechanisms of therapeutic drugs in chronic inflammatory diseases) that aim to tackle and cure diseases characterized by chronic inflammation.
Dr. Maria De Fenza
Prof. Vincenzo Pavone
Dr. Daniele D'Alonzo
Dr. Giuseppe Castellano
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- dysregulated chemotaxis
- chronic inflammation
- ocular diseases
- focal segmental glomerulosclerosis
- acute kidney disease
- new pharmaceutical targets
- innovative pharmaceutic treatments and formulations
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
